Back to top
more

Quanterix (QTRX)

(Real Time Quote from BATS)

$17.80 USD

17.80
88,562

-0.08 (-0.45%)

Updated May 16, 2024 12:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

SmileDirectClub (SDC) New Alliances Aid, Macro Woes Hurt

by Zacks Equity Research

SmileDirectClub (SDC) is focused on developing transformative innovations to serve the growing needs of the current customer base and expanded segments of higher-income demographics.

Here's Why You Should Invest in Edward Lifesciences (EW) Now

by Zacks Equity Research

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of TAVR and a solid balance sheet.

Syneos Health (SYNH) Declares Strategic Partnership With Oracle

by Zacks Equity Research

Syneos Health (SYNH) announces an expanded collaboration with Oracle to accelerate patient recruitment capabilities.

Bruker (BRKR) Inks Fraport Framework Contract for ETD Systems

by Zacks Equity Research

Bruker's (BRKR) DE-tector flex system uses a non-radioactive ionization source and is approved by national regulatory bodies and ECAC.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN) on improvement in testing volume across all its businesses.

Insulet (PODD) Expands Omnipod 5 Even As Macro Woes Linger

by Zacks Equity Research

Insulet's (PODD) international expansion efforts are aligned with its long-term growth profile.

QIAGEN's (QGEN) New API Streamlines Access to BKB Data

by Zacks Equity Research

QIAGEN (QGEN) introduces API to give easier access to the QIAGEN Biomedical Knowledge Base.

NanoString (NSTG) Grows in Translational Research With CRO Deals

by Zacks Equity Research

According to NanoString (NSTG), SMI's unique ability to interrogate both RNA and proteins at ultra-high plex with subcellular resolution has made it a one-of-a-kind tool.

Thermo Fisher (TMO) to Advance Clinical Research With New Pact

by Zacks Equity Research

Thermo Fisher's clinical research division will aid in increasing community health clinics' capacity to participate in clinical studies.

Alcon (ALC) Surgical Advances With New Data on AcrySof IQ Vivity

by Zacks Equity Research

Alcon's (ALC) Vivity Registry study data highlights the lens's versatility in treating a wide range of patients.

Align Technologies (ALGN) Brings New Upgrades for Oral Health

by Zacks Equity Research

Align Technologies (ALGN) introduces a series of software innovations to accelerate the digital practice transformation.

Globus Medical (GMED) Launches NuVasive's NSO in Global Market

by Zacks Equity Research

Globus Medical's (GMED) Precice Bone Transport is a less intrusive treatment that reduces complications for both the patient and the surgeon and is designed for various bone abnormalities.

National Vision (EYE) Gains From Store Opening Amid Macro Woes

by Zacks Equity Research

In terms of store expansion, National Vision (EYE) continues to see a sizable new opportunity with growth for the coming years.

Thermo Fisher (TMO) Adds New Platform to CTS Product Portfolio

by Zacks Equity Research

Thermo Fisher (TMO) launches the next-generation Gibco CTS Detachable Dynabeads platform.

Here's Why You Should Retain Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Bruker (BRKR), backed by the performance of the CALID and NANO groups and strength in acquisitions.

Exact Sciences (EXAS) Gains From New Buyouts Amid Rising Costs

by Zacks Equity Research

Exact Sciences (EXAS) is improving customer experience by making it simpler to order Cologuard electronically and continue re-screening of patients every three years.

Align Technologies (ALGN) Set to Acquire Cubicure GmbH

by Zacks Equity Research

Align Technologies (ALGN) announces acquisition of direct 3D printing pioneer Cubicure GmbH, backed by years of successful collaboration.

Boston Scientific (BSX) WATCHMAN FLX Pro Gets FDA Approval

by Zacks Equity Research

Boston Scientific's (BSX) latest device features a polymer coating, visualization markers and a broader size matrix to treat a wider range of patients.

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS), backed by Cologuard growth and upbeat guidance.

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) on the RMS segment's continued growth and upbeat guidance.

Abbott (ABT) to Advance Diabetes Care With New Acquisition

by Zacks Equity Research

Abbott's (ABT) recent deal will enable it to create more interconnected solutions to improve the personalization and accuracy of diabetes control.

Here's Why You Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL), owing to the strong prospect of the advanced services portfolio.

Why You Should Add Haemonetics (HAE) to Your Portfolio Now

by Zacks Equity Research

Haemonetics' (HAE) share price is likely to grow, backed by solid business performance across all its segments.

Charles River (CRL) Gains From Global Demand Amid FX Woes

by Zacks Equity Research

Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.

Here's Why You Should Retain Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) on growth in the legacy business and upbeat guidance.